TARO PHARMACEUTICAL INDS LTD's ticker is TARO and the CUSIP is M8737E108. A total of 105 filers reported holding TARO PHARMACEUTICAL INDS LTD in Q1 2019. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $555,000 | -21.1% | 6,500 | 0.0% | 0.02% | -18.5% |
| Q1 2019 | $703,000 | +225.5% | 6,500 | +195.5% | 0.03% | +285.7% |
| Q3 2018 | $216,000 | -62.5% | 2,200 | -60.0% | 0.01% | -61.1% |
| Q4 2017 | $576,000 | -7.1% | 5,500 | 0.0% | 0.02% | -5.3% |
| Q3 2017 | $620,000 | +0.6% | 5,500 | 0.0% | 0.02% | +5.6% |
| Q2 2017 | $616,000 | +62.5% | 5,500 | +111.5% | 0.02% | +63.6% |
| Q2 2016 | $379,000 | +1.9% | 2,600 | 0.0% | 0.01% | -15.4% |
| Q1 2016 | $372,000 | -7.5% | 2,600 | 0.0% | 0.01% | -7.1% |
| Q4 2015 | $402,000 | +8.1% | 2,600 | 0.0% | 0.01% | +16.7% |
| Q3 2015 | $372,000 | -16.4% | 2,600 | -16.1% | 0.01% | 0.0% |
| Q2 2015 | $445,000 | +1.8% | 3,100 | 0.0% | 0.01% | +9.1% |
| Q1 2015 | $437,000 | -4.8% | 3,100 | 0.0% | 0.01% | -8.3% |
| Q4 2014 | $459,000 | -3.8% | 3,100 | 0.0% | 0.01% | +9.1% |
| Q3 2014 | $477,000 | +9.7% | 3,100 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $435,000 | – | 3,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 85,205 | $9,416,000 | 7.01% |
| FORT, L.P. | 149,014 | $16,468,000 | 5.67% |
| Strategic Global Advisors, LLC | 80,231 | $11,336,000 | 4.23% |
| MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 701,900 | $77,567,000 | 3.19% |
| Ativo Capital Management LLC | 78,727 | $8,700,000 | 2.01% |
| Analyst IMS Investment Management Services Ltd. | 31,438 | $3,474,000 | 1.47% |
| Parametrica Management Ltd | 4,327 | $478,000 | 1.32% |
| Freestone Capital Holdings, LLC | 89,005 | $9,836,000 | 0.90% |
| RPG Investment Advisory, LLC | 19,580 | $2,163,000 | 0.68% |
| MERITAGE PORTFOLIO MANAGEMENT | 38,465 | $4,251,000 | 0.47% |